Pentazocine
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph (hydrochloride) Monograph (lactate) |
| Pregnancy category |
|
| Routes of administration | By mouth, intramuscular, intravenous |
| Drug class | κ-Opioid receptor agonist; μ-Opioid receptor agonist–antagonist; Opioid analgesic; Hallucinogen |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | ~20% orally |
| Metabolism | Hepatic |
| Onset of action | 15 min |
| Elimination half-life | 2 to 3 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.006.032 |
| Chemical and physical data | |
| Formula | C19H27NO |
| Molar mass | 285.431 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Pentazocine, sold under the brand name Talwin among others, is an opioid analgesic medication used to treat moderate to severe pain. Pentazocine activates (agonizes) κ-opioid receptors (KOR) and μ-opioid receptors (MOR). It shares many of the side effects of other opioids like constipation, nausea, itching, drowsiness, and respiratory depression, but, unlike most other opioids, it fairly frequently causes hallucinations, nightmares, and delusions. It is also, unlike most other opioids, subject to a ceiling effect, which is when at a certain dose no more pain relief is obtained by increasing the dose any further.
Chemically it is classed as a benzomorphan and it comes in two enantiomers.
It was patented in 1960 and approved for medical use in 1964. Usually, in its oral formulations, it is combined with naloxone so as to prevent people from crushing the tablets, dissolving them in saline and injecting them for a high (as orally administered naloxone produces no opioid-negating effects as it has no oral bioavailability, whereas intravenous or intramuscular administration does).